GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jasper Therapeutics Inc (NAS:JSPR) » Definitions » EPS without NRI

Jasper Therapeutics (Jasper Therapeutics) EPS without NRI : $-19.20 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Jasper Therapeutics EPS without NRI?

Jasper Therapeutics's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-1.03. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.20.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -123.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Jasper Therapeutics's EPS without NRI or its related term are showing as below:

JSPR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -123.3   Med: -123.3   Max: -123.3
Current: -123.3

During the past 4 years, Jasper Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -123.30% per year. The lowest was -123.30% per year. And the median was -123.30% per year.

JSPR's 3-Year EPS without NRI Growth Rate is ranked worse than
98.31% of 1298 companies
in the Biotechnology industry
Industry Median: 5.15 vs JSPR: -123.30

Jasper Therapeutics's EPS (Diluted) for the three months ended in Mar. 2024 was $-1.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.13.

Jasper Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-1.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.13.


Jasper Therapeutics EPS without NRI Historical Data

The historical data trend for Jasper Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jasper Therapeutics EPS without NRI Chart

Jasper Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EPS without NRI
-5.50 -32.41 -138.73 -61.27

Jasper Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.47 -1.54 -1.63 -15.00 -1.03

Competitive Comparison of Jasper Therapeutics's EPS without NRI

For the Biotechnology subindustry, Jasper Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jasper Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Jasper Therapeutics's PE Ratio without NRI falls into.



Jasper Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jasper Therapeutics  (NAS:JSPR) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Jasper Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Jasper Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Jasper Therapeutics (Jasper Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2200 Bridge Parkway, Suite No. 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Executives
Thomas G Wiggans director
William Lis director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jeetinder Singh Mahal officer: Chief Operating Officer C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Ron Martell director, officer: President, CEO & Director PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Scott C. Brun director C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Edwin Jonathan Tucker officer: Chief Medical Officer C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Anna Louise French director C/O QIMING U.S. HEALTHCARE, 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Kurt Von Emster director, 10 percent owner 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Gary E Rieschel 10 percent owner
Qiming U.s. Healthcare Fund Ii, L.p. 10 percent owner 350 106TH AVENUE NE, 1ST FLOOR, BELLEVUE WA 98004
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Mark Mcdade 10 percent owner C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Qiming U.s. Healthcare Gp Ii, Llc 10 percent owner 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004

Jasper Therapeutics (Jasper Therapeutics) Headlines

From GuruFocus

Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

By Stock market mentor Stock market mentor 02-03-2023

Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023

By Stock market mentor Stock market mentor 01-30-2023